"As per available data, the number of serious adverse events of deaths in clinical trials reported during the last three years - 2010, 2011 and 2012 - were 668, 438 and 436, respectively," Minister for Health and Family Welfare Ghulam Nabi Azad said in a written reply to a question in the Lok Sabha.
However, deaths attributable to clinical trials were 22, 16 and 16 respectively during these three years, he said.
The minister said government has taken a number of steps to strengthen the approval procedures and monitoring mechanism for clinical trials and to ensure safety, rights and well-being of trial subjects, which includes the amendments notified in the Drugs and Cosmetics Rules, 1945.
In a bid to regulate the booming clinical trial industry in India, government had earlier this month set up four committees to monitor and ensure accountability during such tests that have seen 2,242 deaths in the past five years.
So far, there was no procedure in place to ensure accountability of this hitherto unregulated sector which is worth USD 500 million in India.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
